Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Poorer Countries Need Help With H1N1
Poorer countries in Africa, Asia and Latin America are far from ready to deal with an H1N1 pandemic, and will need help to develop stockpiles

Availability Of IVF Treatment In UK Still Poor Compared With Rest Of Europe
Commenting on the news announced today by ESHRE"s European IVF monitoring consortium on the improvements in the quality, safety and efficacy of ART, Clare Lewis-Jones MBE, Chief Executive of Infertility Network UK said "We are angry that although the UK pioneered infertility treatment, we are still among the lowest providers in Europe of NHS treatment, and these figures show that availability in the UK is less than one third of that in Denmark. Recent measures announced by the Government to encourage implementation of the NICE Guideline have led to an improvement in the provision in some areas but more needs to be done by Primary Care Trusts in England to ensure that patients have equal and timely access to the full range of treatment recommended by NICE, and to tackle the ongoing variations in provision that exist across the country.
News of the day
Study Looks At HIV, Risk Behaviors Among Male Clients Of Sex Workers In Tijuana, Mexico
"A large percentage" of U.S. and Mexican men who regularly engage in sexual activity with sex workers in Tijuana, Mexico, do not use condoms and have a history of substance and alcohol use, according to a study published in the online journal AIDS, the Los Angeles Times" blog "L.A. Now" reports. The study, by researchers from Mexico and the University of California-San Diego, surveyed 400 men - both Mexico and U.S. residents - and found that half of the men had unprotected sex with a female sex worker within the last four months. Researchers noted that although Tijuana authorities require that sex workers be registered and tested regularly for HIV, "only about half of [sex workers] have registered or been tested," according to the blog. Thomas Patterson of the UC-San Diego"s department of psychiatry and the Veterans Affairs health center, said the findings indicate a need for an educational campaign targeting men who frequent sex workers (Perry, 7/11).
Public Health

AIMSPRO Is Awarded TGA Orphan Status For The Treatment Of Amyotrophic Lateral Sclerosis

Privately owned UK biotech company Daval International Limited has been informed by Australia"s Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig"s disease. AIMSPRO has already achieved TGA Orphan Status for the treatment of Krabbe Leukodystrophy (Krabbe"s disease). Daval is now evaluating an international, multi-centre, placebo controlled, Randomised Clinical Trial to determine whether later stage ALS patients with poor respiratory function can be seen to benefit from the medication under double-blind conditions. AIMSPRO is a new generation biological medicine which is d and manufactured in Australia. It is derived from hyperimmune caprine serum and is currently under Phase II trialling in Europe for advanced Scleroderma and for bladder dysfunction in Secondary Progressive Multiple Sclerosis. Both trials are expected to report in the first quarter of 2010. Additional open label experience with AIMSPRO, over an extended period, has led Daval to consider Proof of Concept studies in Adhesive Arachnoiditis, treatment resistant Myasthenia Gravis and Psoriatic arthritis. AIMSPRO is listed on the Export Only section of the Australian Therapeutic Goods Registry and is imported into Europe by Biotec Distribution (Wales) Limited for clinical trial and "named patient use" purposes. The veterinary form of the product, Ceremben(R) has shown efficacy, safety and tolerability in studies addressing critically important indications in standardbred and thoroughbred horses. The Australian regulator, the APVMA, has recently awarded Ceremben a Research Permit, which will enable confirmatory equine field trials to be rapidly completed. Ceremben is also being developed as a potential canine and feline anti-inflammatory agent. Daval International Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009